YL3147
YL3147 is a ferroptosis inhibitor. YL3147 also acts as a radical-trapping antioxidant that directly prevents the spread of lipid peroxidation and blocks ferroptosis. YL3147 exerts significant cardioprotective effects in mouse cardiomyopathy models. YL3147 can be used in studies related to cardiomyopathy.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3123207-48-4
- 分子式: C25H27FN4
- 分子量:402.51
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
YL3147 (48 h) protects ES-2, AC16, HT1080, and PANC-1 cells from Erastin (HY-15763)-induced ferroptosis with EC50 values of 0.8, 0.8, 0.43, and 0.92 nM, respectively[1].
YL3147 (0.01-1 μM; 10-12 h) effectively alleviates Erastin (HY-15763)-induced lipid peroxidation in ES-2 and AC16 cells, as well as ROS production in ES-2 cells[1].
YL3147 (72 h) exhibits low cytotoxicity against various human normal cell lines, with a CC50 value greater than 10 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Multiple normal human cell lines (BEAS-2B, HUVEC, AC16, GES-1, HK-2, HaCaT, ARPE-19, hTERT-HPNE)
-
Concentration:/
-
Incubation Time:72 h
-
Result:Exhibited minimal cytotoxicity, with CC50 values >10 μM across all tested normal cell lines.
| Species | Dose | Route | AUC0-t | AUC0-∞ | Cmax | CL | Vz/F | T1/2 | Tmax | MRT0-t | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | p.o. | 3794.61 μg/L·h | 3800.28 μg/L·h | 584.18 μg/L | 2.63 L/h/kg | 9.28 L/kg | 2.44 h | 1.00 h | 4.65 h | 53.04 % |
| Mice[1] | 10 mg/kg | i.v. | 7022.24 μg/L·h | 7078.71 μg/L·h | 2537.57 μg/L | 1.49 L/h/kg | 6.94 L/kg | 3.35 h | 0.08 h | 4.31 h | / |
| Mice[1] | 10 mg/kg | i.p. | 5033.34 μg/L·h | 5050.96 μg/L·h | 549.69 μg/L | 1.98 L/h/kg | 8.31 L/kg | 2.91 h | 0.25 h | 6.08 h | / |
YL3147 (200 mg/kg; p.o.; single dose) is well tolerated in BALB/c mice, with no acute toxicity or organ injury detected[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (8-week-old male; acute Doxorubicin-induced cardiomyopathy model)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:i.p.; single dose 2 hours prior to doxorubicin
-
Result:Significantly improved cardiac function, including increased ejection fraction, cardiac output, and stroke volume, relative to vehicle-treated mice.
Prolonged survival and reduced mortality relative to vehicle-treated mice.
Markedly reduced doxorubicin-induced elevation in serum lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) levels.
Suppressed increases in myocardial malondialdehyde (MDA) content and mRNA levels of cardiac stress gene Myh7 and ferroptosis-related marker Ptgs2.
Preserved cardiomyocyte structure, attenuated cardiac fibrosis, and reduced 4-hydroxynonenal (4-HNE) immunopositivity in heart tissue.
-
Animal Model:C57BL/6 (8-week-old male; chronic doxorubicin-induced cardiomyopathy model)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; daily; 3 consecutive weeks, starting 3 days before first doxorubicin dose
-
Result:Reduced mortality and attenuated weight loss relative to vehicle-treated mice.
Attenuated doxorubicin-induced ventricular remodeling, with improved ejection fraction, fractional shortening, cardiac output, and stroke volume relative to vehicle-treated mice.
Reduced serum levels of cardiac injury markers LDH and CK-MB relative to vehicle-treated mice.
Decreased myocardial MDA content and attenuated upregulation of Myh7 and Ptgs2 mRNA expression relative to vehicle-treated mice.
Preserved cardiomyocyte architecture, reduced cardiac fibrosis, and lowered tissue lipid peroxidation (4-HNE immunopositivity) relative to vehicle-treated mice.
Caused no significant changes in body weight, cardiac function parameters, serum organ damage markers (ALT, AST, creatinine), or histopathological architecture of major organs when used as monotherapy.
化学情報
-
CAS 番号 3123207-48-4
-
分子量 402.51
-
分子式 C25H27FN4
-
SMILES
FC1=CC(C2=CC3=C(CNC4=CC=CC=C4N3)C(N5CC(N(CC5)C)C)=C2)=CC=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
YL3147 関連分類
HY-181548 関連分類
Powered by Bioz